The European Commission has approved expanded use of a Bristol-Myers Squibb hepatitis C drug to include patient populations with decompensated cirrhosis, HIV-1 coinfection and post-liver transplant recurrence of the virus.
The Centers for Disease Control and Prevention (CDC) is urging dialysis providers to assess and improve infection control practices, in part because the agency has received an increased number of reports of newly acquired HCV infection among patients undergoing hemodialysis.
Vertical transmission, or the spread of infection from mother to baby during childbirth, is the most common way that children get hepatitis C. However, it turns out that these children are rarely tested for the disease.
A multi-study analysis shows that a majority of patients with hepatitis C maintained sustained virological response five years after they were treated but researchers found higher risk of reinfection among patients in two subgroups.
Community health centers screen less than 10% of baby boomer patients (and more men than women) for hepatitis C, a much lower percentage than recommended by national guidelines revised in 2013, according to a recently published study.
Even with direct-acting antivirals, not all patients with chronic hepatitis C can be cured. That might be because patients develop antibodies to interferon, a drug that is still part of DAA regimens, Italian researchers report.